NCT07098923

Brief Summary

In China, the chronic kidney disease (CKD) incidence rate is as high as 10.8%. Renal replacement therapy plays an critical role in the later stage of CKD and becomes mandatory, as end-stage renal disease (ESRD) is unavoidable in progressive CKD. Peritoneal dialysis (PD) has becoming an essential alternative treatment for patient with end-stage renal disease (ESRD). Hypertension is common among ESRD patients receiving PD treatment, with a prevalence rate of 80% -90%, It is major cause for cardiovascular related complications and deaths among ESRD patients. Therefore hypertension increases the cardiovascular disease risk among the patients of ESRD and at the same time plays an independent risk for the progression of ESRD. Most studies uses average blood pressure as a risk indicator, but in recent years, more evidence has shown that blood pressure variability (BPV), the degree of fluctuation of blood pressure for a long period, is an additional risk factors for cardiovascular events.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
55

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 2, 2024

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 30, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 16, 2024

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

July 23, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

August 1, 2025

Completed
Last Updated

August 1, 2025

Status Verified

July 1, 2025

Enrollment Period

6 months

First QC Date

July 23, 2025

Last Update Submit

July 30, 2025

Conditions

Keywords

exerciseresistanceperitoneal dialysisblood pressurecardiovascular systemBlood Pressure Variability

Outcome Measures

Primary Outcomes (4)

  • Difference between the coefficient of variation of mean daytime Systolic Blood Pressure from the baseline to the end of the study

    Change in the coefficient of variation of mean daytime Systolic Blood Pressure as assessed by Ambulatory Blood Pressure Monitoring.

    Baseline/12Weeks

  • Difference between the Coefficient of variation of mean daytime Diastolic Blood Pressure from the baseline to the end of the study

    Change in the Coefficient of variation of mean daytime Diastolic Blood Pressure as assessed by Ambulatory Blood Pressure Monitoring

    Baseline/12Weeks

  • Difference between the Coefficient of Variation of mean nighttime Systolic Blood Pressure from the baseline to the end of the study

    Change in the Coefficient of Variation of mean nighttime Systolic Blood Pressure as assessed by Ambulatory Blood Pressure Monitoring

    Baseline/12Weeks

  • Difference between the Coefficient of Variation of mean nighttime Diastolic Blood Pressure from the baseline to the end of the study

    Change in the Coefficient of Variation of mean nighttime Diastolic Blood Pressure as assessed by Ambulatory Blood Pressure Monitoring.

    Baseline/12Weeks

Secondary Outcomes (2)

  • Difference between the Coefficient of Variation of 24 Hours Systolic Blood Pressure from the baseline to the end of the study

    Baseline/12Weeks

  • Difference between the Coefficient of Variation of 24 Hours Diastolic Blood Pressure from the baseline to the end of the study

    Baseline/12Weeks

Study Arms (2)

control group

NO INTERVENTION

Routine peritoneal dialysis care, health education, daily activity guidance, and dietary counseling were provided in accordance with the dietary guidelines for chronic kidney disease

Exercise group

EXPERIMENTAL

Routine peritoneal dialysis care, health education, daily activity guidance, and dietary counseling were provided in a manner consistent with the care given to the control group-to avoid performance bias. In addition to routine basic care and treatment, the exercise group performed a combination of aerobic and resistance exercise

Behavioral: combination of aerobic and resistance exercise

Interventions

Aerobic exercise: The main form is walking(gait), which includes three parts: warm-up, walking, and relaxation. Exercise time and frequency: 30-60 minutes of exercise per day, 3-5 times per week. Resistance exercise: Mainly uses elastic bands to enhance resistance exercise, since the risks of increased intra-abdominal pressure and fluid leakage in peritoneal dialysis patients is high, Investigator considered selective resistance exercise especially for limb and shoulder joint exercises. Patients can choose 3-5 muscle groups based on individual conditions, with each action 10-15 times and maintained for 10 seconds. Start with 2 sets of resistance exercise and then gradually increase to 3-5 sets, with 2-3 minutes of rest between each sets. Exercise frequency and duration: 2 times a week (non-consecutive days), 20 minutes each time.

Also known as: Aerobic exercise, resistance exercise
Exercise group

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Dialysis time ≥ 3 months, a stable condition;
  • Age ≥ 18 years old;
  • Hypertension (blood pressure\>140 and/or 90 mmHg or currently under antihypertensive drugs), antihypertensive drugs was not changed or replaced during the complete trial;
  • Patients with regular and sufficient peritoneal dialysis with kt/v\>1.7, high compliance, and voluntary participation.

You may not qualify if:

  • Blood pressure more than - systolic blood pressure ≥ 180mmHg, diastolic blood pressure ≥ 110mmHg;
  • Severe anaemia Hb ≤ 60g;
  • Cardiac function Class IV - In accordance with The New York Heart Association classification system, patients with severe cardiac disease resulting in inability to perform any physical activity without discomfort (If any physical activity is undertaken, discomfort is increased) or symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest.
  • Using erythropoietin;
  • There have been recent acute cardiovascular and cerebrovascular events, including vascular embolism, surgery, trauma, etc.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The affiliated hospital of Xuzhou Medical University

Xuzhou, Jiangsu, 221000, China

Location

MeSH Terms

Conditions

Renal Insufficiency, ChronicMotor Activity

Interventions

ExerciseResistance Training

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsBehavior

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological PhenomenaExercise TherapyRehabilitationAftercareContinuity of Patient CarePatient CareTherapeuticsPhysical Therapy ModalitiesPhysical Conditioning, Human

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
CARE PROVIDER, INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

July 23, 2025

First Posted

August 1, 2025

Study Start

February 2, 2024

Primary Completion

July 30, 2024

Study Completion

October 16, 2024

Last Updated

August 1, 2025

Record last verified: 2025-07

Locations